CAR T cell immunotherapy for human cancer

Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia

Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849

Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia

Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509

Cancer regression in patients after transfer of genetically engineered lymphocytes

Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., et al. (2006) · Science · doi:10.1126/science.1129003 · Cited by 2,603

Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2

Morgan, R. A., Yang, J. C.-H., Kitano, M., Dudley, M. E., Laurençot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,564

Adoptive cell transfer as personalized immunotherapy for human cancer

Rosenberg, S. A., & Restifo, N. P. (2015) · Science · doi:10.1126/science.aaa4967 · Cited by 2,545

T cell exclusion, immune privilege, and the tumor microenvironment

Joyce, J. A., & Fearon, D. T. (2015) · Science · doi:10.1126/science.aaa6204 · Cited by 2,539

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

Kalos, M. D., Levine, B. L., Porter, D. L., Katz, S. I., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,417

Advanced biomaterials for cancer immunotherapy

Yang, F., Shi, K. Y., Jia, Y., Hao, Y., Peng, J., & Qian, Z. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0372-z · Cited by 122

Personalized Nanovaccine Coated with Calcinetin-Expressed Cancer Cell Membrane Antigen for Cancer Immunotherapy

Xiong, X., Zhao, J., Pan, J., Liu, C., Guo, X., & Zhou, S. (2021) · Nano Letters · doi:10.1021/acs.nanolett.1c03004 · Cited by 115

Engineering switchable and programmable universal CARs for CAR T therapy

Liu, D., Zhao, J., & Song, Y. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0763-0 · Cited by 118

Towards efficient immunotherapy for bacterial infection

McCulloch, T. R., Wells, T. J., & Souza-Fonseca-Guimarães, F. (2021) · Trends in Microbiology · doi:10.1016/j.tim.2021.05.005 · Cited by 116

Engineering chimeric antigen receptor neutrophils from human pluripotent stem cells for targeted cancer immunotherapy

Chang, Y., Syahirah, R., Wang, X., Jin, G., Torregrosa‐Allen, S. E., Elzey, B. D., Hummel, S. N., Wang, T., Li, C., Lian, X. L., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111128 · Cited by 117

mRNA delivery systems for cancer immunotherapy: Lipid nanoparticles and beyond

Sentí, M. E., del Valle, L. G., & Schiffelers, R. M. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115190 · Cited by 124

Circular Bispecific Aptamer-Mediated Artificial Intercellular Recognition for Targeted T Cell Immunotherapy

Yang, Y. P., Sun, X., Xu, J., Cui, C., Yazd, H. S., Pan, X., Zhu, Y., Chen, X., Li, X., Li, J., et al. (2020) · ACS Nano · doi:10.1021/acsnano.9b09884 · Cited by 112

Metabolic Interdependency of Th2 Cell-Mediated Type 2 Immunity and the Tumor Microenvironment

Schreiber, S., Hammers, C. M., Kaasch, A. J., Schraven, B. L., Dudeck, A., & Kahlfuß, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.632581 · Cited by 113

Immunologically modified MnFe2O4 nanoparticles to synergize photothermal therapy and immunotherapy for cancer treatment

Zhou, B., Wu, Q., Wang, M., Hoover, A. R., Wang, X., Zhou, F., Towner, R. A., Smith, N., Saunders, D., Song, J., et al. (2020) · Chemical Engineering Journal · doi:10.1016/j.cej.2020.125239 · Cited by 109

In-Vivo Induced CAR-T Cell for the Potential Breakthrough to Overcome the Barriers of Current CAR-T Cell Therapy

Xin, T., Li, C., Zhou, C., Zhao, Y., Hu, Z., & Wu, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.809754 · Cited by 115

Adoptive cell therapy for cancer treatment

Du, S., Yan, J., Xue, Y., Zhong, Y., & Dong, Y. (2023) · Exploration · doi:10.1002/exp.20210058 · Cited by 123

High-efficiency transgene integration by homology-directed repair in human primary cells using DNA-PKcs inhibition

Selvaraj, S., Feist, W. N., Viel, S., Vaidyanathan, S., Dudek, A. M., Gastou, M., Rockwood, S. J., Ekman, F. K., Oseghale, A., Xu, L., et al. (2023) · Nature Biotechnology · doi:10.1038/s41587-023-01888-4 · Cited by 106

Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?

Liu, Y., Bewersdorf, J. P., Stahl, M. F., & Zeidan, A. M. (2018) · Blood Reviews · doi:10.1016/j.blre.2018.12.001 · Cited by 112

Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia

Zhao, J., Song, Y., & Liu, D. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0705-x · Cited by 111

Recent Advances in Immunotherapy for Hepatocellular Carcinoma

Nakano, S., Eso, Y., Okada, H., Takai, A., Takahashi, K., & Seno, H. (2020) · Cancers · doi:10.3390/cancers12040775 · Cited by 109

Dawn of lipid nanoparticles in lymph node targeting: Potential in cancer immunotherapy

Nakamura, T., & Harashima, H. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.003 · Cited by 109

Emerging CAR-T Cell Therapy for the Treatment of Triple-Negative Breast Cancer

Dees, S., Ganesan, R., Singh, S., & Grewal, I. S. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0385 · Cited by 109

Cell/Bacteria‐Based Bioactive Materials for Cancer Immune Modulation and Precision Therapy

Pan, H., Zheng, M., Ma, A.-Q., Liu, L., & Cai, L. (2021) · Advanced Materials · doi:10.1002/adma.202100241 · Cited by 109

An evolved AAV variant enables efficient genetic engineering of murine T cells

Nyberg, W. A., Ark, J., To, A., Clouden, S., Reeder, G. C., Muldoon, J. J., Chung, J.-Y., Xie, W. H., Allain, V., Steinhart, Z., et al. (2023) · Cell · doi:10.1016/j.cell.2022.12.022 · Cited by 113

In vivo generated human CAR T cells eradicate tumor cells

Agarwal, S., Weidner, T., Thalheimer, F. B., & Buchholz, C. J. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1671761 · Cited by 112

Microfluidic Cell Stretching for Highly Effective Gene Delivery into Hard-to-Transfect Primary Cells

Hur, J., Park, I., Lim, K. M., Doh, J., Cho, S., & Chung, A. J. (2020) · ACS Nano · doi:10.1021/acsnano.0c05169 · Cited by 106

Nanoengineered CAR‐T Biohybrids for Solid Tumor Immunotherapy with Microenvironment Photothermal‐Remodeling Strategy

Chen, Z., Pan, H., Luo, Y., Yin, T., Zhang, B., Liao, J., Wang, M., Tang, X., Huang, G., Deng, G., et al. (2021) · Small · doi:10.1002/smll.202007494 · Cited by 109

Advancements and Obstacles of CRISPR-Cas9 Technology in Translational Research

You, L., Tong, R., Li, M., Liu, Y., Xue, J., & Lü, Y. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.02.008 · Cited by 112

CAR-T “the living drugs”, immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy

Liu, D. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0819-1 · Cited by 112

Broadly neutralizing antibody–derived CAR T cells reduce viral reservoir in individuals infected with HIV-1

Liu, B., Zhang, W., Xia, B., Jing, S., Du, Y., Zou, F., Li, R., Lu, L., Chen, S., Li, Y., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci150211 · Cited by 112

Engineering the next generation of CAR-NK immunotherapies

Biederstädt, A., & Rezvani, K. (2021) · International Journal of Hematology · doi:10.1007/s12185-021-03209-4 · Cited by 114

Broad Cytotoxic Targeting of Acute Myeloid Leukemia by Polyclonal Delta One T Cells

Lorenzo, B. D., Simões, A. E. S., Caiado, F., Tieppo, P., Correia, D. V., Carvalho, T., da Silva, M. G., Déchanet‐Merville, J., Schumacher, T. N., Prinz, I., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0647 · Cited by 106

The Cellular Immunotherapy Revolution: Arming the Immune System for Precision Therapy

Paucek, R. D., Baltimore, D., & Li, G. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.02.002 · Cited by 104

Challenges and Future Prospects of Precision Medicine in Psychiatry

Manchia, M., Pisanu, C., Squassina, A., & Carpiniello, B. (2020) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s198225 · Cited by 109

An algorithm to quantify intratumor heterogeneity based on alterations of gene expression profiles

Li, M., Zhang, Z., Li, L., & Wang, X. (2020) · Communications Biology · doi:10.1038/s42003-020-01230-7 · Cited by 100

The Role of Trogocytosis in the Modulation of Immune Cell Functions

Miyake, K., & Karasuyama, H. (2021) · Cells · doi:10.3390/cells10051255 · Cited by 109

Efficient engineering of human and mouse primary cells using peptide-assisted genome editing

Zhang, Z., Baxter, A. E., Ren, D., Qin, K., Chen, Z., Collins, S. M., Huang, H., Komar, C. A., Bailer, P. F., Parker, J. B., et al. (2023) · Nature Biotechnology · doi:10.1038/s41587-023-01756-1 · Cited by 113

Co-delivery of Dihydroartemisinin and Pyropheophorbide-Iron Elicits Ferroptosis to Potentiate Cancer Immunotherapy

Han, W., Duan, X., Ni, K., Li, Y., Chan, C., & Lin, W. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2021.121315 · Cited by 103

Towards Immunotherapy for Pediatric Brain Tumors

Wang, S. S., Bandopadhayay, P., & Jenkins, M. R. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.05.009 · Cited by 104

Model‐Based Cellular Kinetic Analysis of Chimeric Antigen Receptor‐T Cells in Humans

Liu, C., Ayyar, V. S., Zheng, X., Chen, W., Zheng, S., Mody, H. R., Wang, W., Heald, D., Singh, A. P., & Cao, Y. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2040 · Cited by 102

CRISPR engineering in organoids for gene repair and disease modelling

Geurts, M. H., & Clevers, H. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-022-00013-5 · Cited by 103

Adenosine Signaling Is Prognostic for Cancer Outcome and Has Predictive Utility for Immunotherapeutic Response

Sidders, B. S., Zhang, P., Goodwin, K., O’Connor, G., Russell, D. L., Borodovsky, A., Armenia, J., McEwen, R. K., Linghu, B., Bendell, J. C., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2183 · Cited by 104

A novel chimeric PD1-NKG2D-41BB receptor enhances antitumor activity of NK92 cells against human lung cancer H1299 cells by triggering pyroptosis

Lu, C., Guo, C., Chen, H., Zhang, H., Zhi, L., Lv, T., Li, M., Niu, Z., Lu, P., & Zhu, W. (2020) · Molecular Immunology · doi:10.1016/j.molimm.2020.04.016 · Cited by 103

Circularly permuted LOV2 as a modular photoswitch for optogenetic engineering

He, L., Tan, P., Zhu, L., Huang, K., Nguyen, N. T., Wang, R., Guo, L. M., Li, L., Yang, Y., Huang, Z., et al. (2021) · Nature Chemical Biology · doi:10.1038/s41589-021-00792-9 · Cited by 102

Present and future of cancer nano-immunotherapy: opportunities, obstacles and challenges

Wang, M., Yu, F., & Zhang, Y. (2025) · Molecular Cancer · doi:10.1186/s12943-024-02214-5 · Cited by 110

Recent advances in small molecule based cancer immunotherapy

Cheng, B., Yuan, W., Su, J., Liu, Y., & Chen, J. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.08.028 · Cited by 101

Ten‐year update of the international registry on cytokine‐induced killer cells in cancer immunotherapy

Zhang, Y., & Schmidt‐Wolf, I. G. H. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29827 · Cited by 99

Delivery technologies for T cell gene editing: Applications in cancer immunotherapy

Atsavapranee, E., Billingsley, M. M., & Mitchell, M. J. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103354 · Cited by 104

The immune cell atlas of human neuroblastoma

Verhoeven, B. M., Mei, S., Olsen, T. K., Gustafsson, K. U., Valind, A., Lindström, A., Gisselsson, D., Fard, S. S., Hagerling, C., Kharchenko, P. V., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100657 · Cited by 100

Magnetic–Acoustic Sequentially Actuated CAR T Cell Microrobots for Precision Navigation and In Situ Antitumor Immunoactivation

Tang, X., Yang, Y., Zheng, M., Yin, T., Huang, G., Lai, Z., Zhang, B., Chen, Z., Xu, T., Ma, T., et al. (2023) · Advanced Materials · doi:10.1002/adma.202211509 · Cited by 101

Towards the development of human immune-system-on-a-chip platforms

Polini, A., del Mercato, L. L., Adriano Barra, A., Zhang, Y. S., Calabi, F., & Gigli, G. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.10.003 · Cited by 101

Recent updates on CAR T clinical trials for multiple myeloma

Lin, Q., Zhao, J., Song, Y., & Liu, D. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1092-1 · Cited by 101

The Human Immunopeptidome Project: A Roadmap to Predict and Treat Immune Diseases

Vizcaíno, J. A., Kubiniok, P., Kovalchik, K. A., Ma, Q., Duquette, J. D., Mongrain, I., Deutsch, E. W., Peters, B., Sette, A., Sirois, I., et al. (2019) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r119.001743 · Cited by 93

A conformation-specific ON-switch for controlling CAR T cells with an orally available drug

Zajc, C. U., Dobersberger, M., Schaffner, I., Mlynek, G., Pühringer, D., Salzer, B., Djinović‐Carugo, K., Steinberger, P., Linhares, A. D. S., Yang, N. J., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1911154117 · Cited by 100

Engineering the Bridge between Innate and Adaptive Immunity for Cancer Immunotherapy: Focus on γδ T and NK Cells

Morandi, F., Yazdanifar, M., Cocco, C., Bertaina, A., & Airoldi, I. (2020) · Cells · doi:10.3390/cells9081757 · Cited by 103

Immunotherapy: an alternative promising therapeutic approach against cancers

Gupta, S. L., Basu, S., Soni, V., & Jaiswal, R. K. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-07525-8 · Cited by 107

Chimeric antigen receptor T ( CAR‐T ) cells: Novel cell therapy for hematological malignancies

Abbasi, S., Totmaj, M. A., Abbasi, M., Hajazimian, S., Goleij, P., Behroozi, J., Shademan, B., Isazadeh, A., & Baradaran, B. (2022) · Cancer Medicine · doi:10.1002/cam4.5551 · Cited by 104

Targeting the Tumor Microenvironment of Leukemia and Lymphoma

Höpken, U. E., & Rehm, A. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.05.001 · Cited by 104

EZH1 repression generates mature iPSC-derived CAR T cells with enhanced antitumor activity

Jing, R., Scarfò, I., Najia, M. A. T., da Rocha, E. L., Han, A., Sanborn, M., Bingham, T., Kubaczka, C., Jha, D. K., Falchetti, M., et al. (2022) · Cell stem cell · doi:10.1016/j.stem.2022.06.014 · Cited by 96

High-Throughput Microfluidic 3D Cytotoxicity Assay for Cancer Immunotherapy (CACI-IMPACT Platform)

Park, D., Son, K., Hwang, Y., Ko, J., Lee, Y., Doh, J., & Jeon, N. L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01133 · Cited by 98

Doxycycline Inducible Chimeric Antigen Receptor T Cells Targeting CD147 for Hepatocellular Carcinoma Therapy

Zhang, R., Wei, D., Liu, Z.-K., Yong, Y., Wei, W., Zhang, Z., Lv, J., Zhang, Z., Chen, Z., & Bian, H. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00233 · Cited by 95

Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of PD-1 immunotherapy

Waite, J. C., Wang, B., Haber, L., Hermann, A., Ullman, E., Ye, X., Dudgeon, D., Slim, R. M., Ajithdoss, D. K., Godin, S., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aba2325 · Cited by 100

Modifying the tumour microenvironment and reverting tumour cells: New strategies for treating malignant tumours

Cheng, Y., Wang, S. B., Liu, J. H., Jin, L., Liu, Y., Li, C. Y., Su, Y., Liu, Y. R., Sang, X., Wan, Q., et al. (2020) · Cell Proliferation · doi:10.1111/cpr.12865 · Cited by 99

Tuning Cancer Fate: Tumor Microenvironment's Role in Cancer Stem Cell Quiescence and Reawakening

Sistigu, A., Musella, M., Galassi, C., Vitale, I., & Maria, R. D. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02166 · Cited by 102

Effective Combinations of Immunotherapy and Radiotherapy for Cancer Treatment

Yu, S., Wang, Y., He, P., Shao, B., Liu, F., Xiang, Z., Yang, T., Zeng, Y., He, T., Ma, J., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.809304 · Cited by 101

The EBMT/EHA CAR-T Cell Handbook

Kröger, N., Gribben, J. G., Chabannon, C., Yakoub‐Agha, I., & Einsele, H. (2022) · Springer eBooks · doi:10.1007/978-3-030-94353-0 · Cited by 106

CD8 + T cell exhaustion in anti‐tumour immunity: The new insights for cancer immunotherapy

Huang, Y., Jia, A., Wang, Y., & Liu, G. (2022) · Immunology · doi:10.1111/imm.13588 · Cited by 96

Boosting Checkpoint Immunotherapy with Biomaterials

Liu, L., Pan, Y., Zhao, C., Huang, P., Chen, X. S., & Rao, L. (2023) · ACS Nano · doi:10.1021/acsnano.2c11691 · Cited by 97

B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases

Haghikia, A., Schett, G. A., & Mougiakakos, D. (2024) · The Lancet Neurology · doi:10.1016/s1474-4422(24)00140-6 · Cited by 96

Immunoscore and its introduction in clinical practice

Galon, J., & Lanzi, A. (2020) · The Quarterly Journal of Nuclear Medicine and Molecular Imaging · doi:10.23736/s1824-4785.20.03249-5 · Cited by 96

Recent Development of Photothermal Agents (PTAs) Based on Small Organic Molecular Dyes

Lv, S., Miao, Y., Liu, D., & Song, F. (2020) · ChemBioChem · doi:10.1002/cbic.202000089 · Cited by 97

Reprogramming Tumor Microenvironment with Photothermal Therapy

Hu, Q., Huang, Z., Duan, Y., Fu, Z., & Liu, B. (2020) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.0c00135 · Cited by 93

The Multifaceted Role of Th1, Th9, and Th17 Cells in Immune Checkpoint Inhibition Therapy

Lee, J., Lozano‐Ruiz, B., Yang, F. M., Fan, D. D., Shen, L., & González-Navajas, J. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.625667 · Cited by 102

Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy

Vitale, I., Sistigu, A., Manic, G., Rudqvist, N.-P., Trajanoski, Z., & Galluzzi, L. (2019) · Trends in Cell Biology · doi:10.1016/j.tcb.2019.01.003 · Cited by 95

Immunotherapy for advanced hepatocellular carcinoma, where are we?

Li, Z., Ding, J., Li, H., Wang, Z., & Wu, J. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188441 · Cited by 95

Approval of First CAR-Ts: Have we Solved all Hurdles for ATMPs?

Seimetz, D., Heller, K., & Richter, J. (2019) · Cell Medicine · doi:10.1177/2155179018822781 · Cited by 90

The Emergence of Universal Immune Receptor T Cell Therapy for Cancer

Minutolo, N. G., Hollander, E. E., & Powell, D. J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00176 · Cited by 98

B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma

Tai, Y., & Anderson, K. C. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1641196 · Cited by 94

Anti-human CD117 CAR T-cells efficiently eliminate healthy and malignant CD117-expressing hematopoietic cells

Myburgh, R., Kiefer, J. D., Russkamp, N. F., Magnani, C. F., Núñez, N. G., Simonis, A., Pfister, S., Wilk, C. M., McHugh, D., Friemel, J., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0818-9 · Cited by 93

Nano-Enhanced Cancer Immunotherapy: Immunology Encounters Nanotechnology

Bockamp, E., Rosigkeit, S., Siegl, D., & Schuppan, D. (2020) · Cells · doi:10.3390/cells9092102 · Cited by 96

Pharmaceutical protein solids: Drying technology, solid-state characterization and stability

Chen, Y., Mutukuri, T. T., Wilson, N. E., & Zhou, Q. T. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.02.016 · Cited by 94

Targeting cellular senescence in cancer and aging: roles of p53 and its isoforms

Beck, J. A., Turnquist, C., Horikawa, I., & Harris, C. C. (2020) · Carcinogenesis · doi:10.1093/carcin/bgaa071 · Cited by 97

Nano-immunotherapy: Unique mechanisms of nanomaterials in synergizing cancer immunotherapy

Liu, Q., Duo, Y., Fu, J., Qiu, M., Sun, Z., Adah, D., Kang, J., Xie, Z., Fan, T., Bao, S., et al. (2020) · Nano Today · doi:10.1016/j.nantod.2020.101023 · Cited by 93

DNA Vaccines: Their Formulations, Engineering and Delivery

Kozak, M., & Hu, J. (2024) · Vaccines · doi:10.3390/vaccines12010071 · Cited by 100

Harnessing and Enhancing Macrophage Phagocytosis for Cancer Therapy

Chen, S., Lai, S. W. T., Brown, C. E., & Feng, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.635173 · Cited by 91

Interleukin 15 in Cell-Based Cancer Immunotherapy

Zhou, Y., Husman, T., Cen, X., Tsao, T., Brown, J., Bajpai, A., Li, M., Zhou, K., & Yang, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137311 · Cited by 92

Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy

Bulliard, Y., Andersson, B. S., Baysal, M. A., Damiano, J. S., & Tsimberidou, A. M. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01504-7 · Cited by 98

The NOTCH–FOXM1 Axis Plays a Key Role in Mitochondrial Biogenesis in the Induction of Human Stem Cell Memory–like CAR-T Cells

Kondo, T., Ando, M., Nagai, N., Tomisato, W., Srirat, T., Liu, B., Mise‐Omata, S., Ikeda, M., Chikuma, S., Nishimasu, H., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-1196 · Cited by 92

Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma

Lin, L., Cho, S., Xing, L., Wen, K., Li, Y., Yu, T., Hsieh, P. A., Chen, H., Kurtoğlu, M., Zhang, Y., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0951-5 · Cited by 92

Advances in the Management of Primary Membranous Nephropathy and Rituximab-Refractory Membranous Nephropathy

Teisseyre, M., Crémoni, M., Boyer‐Suavet, S., Ruetsch-Chelli, C., Graça, D., Esnault, V. L. M., Brglez, V., & Seitz‐Polski, B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.859419 · Cited by 93

CD24: A Novel Target for Cancer Immunotherapy

Panagiotou, Ε., Syrigos, N. K., Charpidou, A. G., Kotteas, E. A., & Vathiotis, I. A. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12081235 · Cited by 93

Delivering metal ions by nanomaterials: Turning metal ions into drug-like cancer theranostic agents

Liu, C., Guo, L., Wang, Y., Zhang, J., & Fu, C. (2023) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2023.215332 · Cited by 90

Traceable Bioinspired Nanoparticle for the Treatment of Metastatic Breast Cancer via NIR‐Trigged Intracellular Delivery of Methylene Blue and Cisplatin

Zhai, Y., Ran, W., Su, J., Lang, T., Meng, J., Wang, G., Zhang, P., & Li, Y. (2018) · Advanced Materials · doi:10.1002/adma.201802378 · Cited by 89

Surface-Engineered Lentiviral Vectors for Selective Gene Transfer into Subtypes of Lymphocytes

Frank, A. M., & Buchholz, C. J. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.10.006 · Cited by 93

Synergistic tumor immunological strategy by combining tumor nanovaccine with gene-mediated extracellular matrix scavenger

Hu, Y., Lın, L., Chen, J., Maruyama, A., Tian, H., & Chen, X. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120114 · Cited by 88

Targeting Radiation-Resistant Prostate Cancer Stem Cells by B7-H3 CAR T Cells

Zhang, Y., He, L., Sadagopan, A., Ma, T., Dotti, G., Wang, Y., Zheng, H., Gao, X. Y., Wang, D., DeLeo, A. B., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0446 · Cited by 89

Autoimmune Disorders of the Nervous System: Pathophysiology, Clinical Features, and Therapy

Bhagavati, S. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.664664 · Cited by 89

Bispecific antibodies in the treatment of multiple myeloma

Devasia, A. J., Chari, A., & Lancman, G. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01139-y · Cited by 94

Antibody-based cancer therapy

Goydel, R. S., & Rader, C. M. (2021) · Oncogene · doi:10.1038/s41388-021-01811-8 · Cited by 93

Recent advances in immunotherapy, immunoadjuvant, and nanomaterial-based combination immunotherapy

Zhou, B., Liu, J., Lin, M., Zhu, J., & Chen, W. R. (2021) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2021.214009 · Cited by 86

Trained immunity: Target for prophylaxis and therapy

Ziogas, A., Bruno, M., van der Meel, R., Mulder, W. J. M., & Netea, M. G. (2023) · Cell Host & Microbe · doi:10.1016/j.chom.2023.10.015 · Cited by 90

CRISPR/Cas9 revitalizes adoptive T-cell therapy for cancer immunotherapy

Ghaffari, S., Khalili, N., & Rezaei, N. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02076-5 · Cited by 91

Targeting Solid Tumors with Bispecific T Cell Engager Immune Therapy

Arvedson, T., Bailis, J. M., Britten, C. D., Klinger, M., Nagorsen, D., Coxon, A., Egen, J. G., & Martin, F. (2021) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-070620-104325 · Cited by 87

Biological and clinical significance of tumour-infiltrating lymphocytes in the era of immunotherapy: a multidimensional approach

de Rodas, M. L., Villalba-Esparza, M., Sanmamed, M. F., Chen, L., Rimm, D. L., & Schalper, K. A. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00984-x · Cited by 98

Host conditioning with IL-1β improves the antitumor function of adoptively transferred T cells

Lee, P., Yamamoto, T. N., Gurusamy, D., Sukumar, M., Yu, Z., Hu‐Li, J., Kawabe, T., Gangaplara, A., Kishton, R. J., Henning, A. N., et al. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20181218 · Cited by 88

Trial Watch: Adoptive cell transfer for oncological indications

Aranda, F., Buqué, A., Bloy, N., Castoldi, F., Eggermont, A. M. M., Cremer, I., Fridman, W. H., Fucikova, J. P., Galon, J., Špíšek, R., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1046673 · Cited by 33

Chimeric Antigen Receptor– and TCR-Modified T Cells Enter Main Street and Wall Street

Barrett, D. M., Grupp, S. A., & June, C. H. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500751 · Cited by 182

Clinical practice: chimeric antigen receptor (CAR) T cells: a major breakthrough in the battle against cancer

Lundh, S. M., Jung, I.-Y., Dimitri, A. J., Vora, A., Melenhorst, J. J., Jadlowsky, J. K., & Fraietta, J. A. (2020) · Clinical and Experimental Medicine · doi:10.1007/s10238-020-00628-1 · Cited by 10

Improving cell reinfusion to enhance the efficacy of chimeric antigen receptor T-cell therapy and alleviate complications

Han, Z., Ma, X., & Ma, G. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e28098 · Cited by 3

Abstract KN01: Updates on engineered T cells as cancer therapies

June, C. H. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-15-kn01